- Report
- January 2026
- 450 Pages
Global
From €4402EUR$5,000USD£3,804GBP
- Report
- June 2025
- 400 Pages
Global
From €4357EUR$4,949USD£3,766GBP
- Report
- February 2026
- 141 Pages
Global
From €3521EUR$3,999USD£3,043GBP
- Report
- September 2025
- 135 Pages
Global
From €3521EUR$3,999USD£3,043GBP
- Report
- November 2025
- 200 Pages
Global
From €6999EUR$7,950USD£6,049GBP
- Report
- August 2025
- 298 Pages
Global
From €4397EUR$4,995USD£3,801GBP
- Report
- September 2025
- 150 Pages
Global
From €4270EUR$4,850USD£3,690GBP
- Report
- May 2025
- 150 Pages
Global
From €4270EUR$4,850USD£3,690GBP
- Report
- May 2025
- 150 Pages
Global
From €4270EUR$4,850USD£3,690GBP
- Report
- September 2025
- 150 Pages
Global
From €4270EUR$4,850USD£3,690GBP
- Report
- January 2026
- 160 Pages
Global
From €2956EUR$3,358USD£2,555GBP
€3477EUR$3,950USD£3,005GBP
- Report
- October 2025
- 160 Pages
Global
From €2956EUR$3,358USD£2,555GBP
€3477EUR$3,950USD£3,005GBP
- Report
- October 2025
- 160 Pages
Global
From €2956EUR$3,358USD£2,555GBP
€3477EUR$3,950USD£3,005GBP
- Report
- October 2025
- 160 Pages
Global
From €2956EUR$3,358USD£2,555GBP
€3477EUR$3,950USD£3,005GBP
- Report
- August 2025
- 150 Pages
Global
From €2956EUR$3,358USD£2,555GBP
€3477EUR$3,950USD£3,005GBP
- Training
- September 2026
- 2 Days
Global
€1556EUR$1,829USD£1,299GBP
€1795EUR$2,110USD£1,499GBP
- Report
- July 2025
- 150 Pages
Africa
From €5238EUR$5,950USD£4,527GBP
- Report
- August 2025
- 85 Pages
United States
From €3081EUR$3,500USD£2,663GBP
- Report
- February 2026
- 150 Pages
United States
From €4270EUR$4,850USD£3,690GBP
- Report
- October 2025
- 97 Pages
Middle East
From €4270EUR$4,850USD£3,690GBP

The Orphan Drug market is a subset of the Pharmaceutical industry that focuses on the development and commercialization of drugs for rare diseases. These drugs are typically developed to treat diseases that affect fewer than 200,000 people in the United States. The Orphan Drug Act of 1983 was passed to incentivize the development of these drugs by providing tax credits, grants, and other incentives to companies that develop them.
The Orphan Drug market has grown significantly in recent years, with more companies entering the market and more drugs being developed. This growth has been driven by advances in medical technology, increased public awareness of rare diseases, and the availability of government incentives.
Some companies in the Orphan Drug market include AbbVie, Amgen, Biogen, Gilead Sciences, and Novartis. Show Less Read more